Do TX, Nguyen HT, Nguyen PTL, Kieu MTT, et al. Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. PLoS One 2026;21:e0345212.
PMID: 41931503